From NASDAQ.: 2025-02-08 23:17:46

Regeneron Pharmaceuticals announced positive three-year results for EYLEA HD in patients with wet age-related macular degeneration. The data showed sustained visual gains and longer treatment intervals for most patients. Patients who switched from EYLEA Injection 2 mg to EYLEA HD also maintained vision improvements. EYLEA HD, developed by Regeneron and Bayer AG, is known as Eylea 8 mg in the EU and Japan. Regeneron holds exclusive rights in the U.S., while Bayer has marketing rights outside the U.S. Both companies share profits from sales of EYLEA and EYLEA HD.



Read more at NASDAQ.: Regeneron : EYLEA HD Shows Sustained Vision Gains In Wet AMD Patients At 3 Years